Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Simon Thezenas

Showing results (31-40 of 57) with videos related to

Pageof 6
Sort By:
Future Oncology (London, England)|February 5, 2014
Prognostic impact of the inclusion of uPA/PAI-1 tumor levels in the current adjuvant treatment decision-making for early breast cancerHaïdar Saadoun, Pierre-Jean Lamy, Simon Thezenas, et al.
Clinical Breast Cancer|January 2, 2018
Serum Vitamin D Levels Affect Pathologic Complete Response in Patients Undergoing Neoadjuvant Systemic Therapy for Operable Breast CancerAkiko Chiba, Rachna Raman, Alexandra Thomas, et al.
BMC Cancer|November 7, 2013
BRCA1 promoter hypermethylation, 53BP1 protein expression and PARP-1 activity as biomarkers of DNA repair deficit in breast cancerWilliam Jacot, Simon Thezenas, Romain Senal, et al.
Breast Cancer Research and Treatment|July 8, 2017
Prognostic impact of the inclusion of uPA/PAI-1 for adjuvant treatment decision-making in ER+/Her2- pN0 early breast cancersMarie Viala, Marie Alexandre, Simon Thezenas, et al.
BMC Cancer|February 1, 2019
The prognostic value of the Tau protein serum level in metastatic breast cancer patients and its correlation with brain metastasesAmélie Darlix, Christophe Hirtz, Simon Thezenas, et al.
The Oncologist|October 22, 2011
Cetuximab plus FOLFIRINOX (ERBIRINOX) as first-line treatment for unresectable metastatic colorectal cancer: a phase II trialEric Assenat, Francoise Desseigne, Simon Thezenas, et al.
Springerplus|July 9, 2016
Meal context and food preferences in cancer patients: results from a French self-report surveyEstelle Guerdoux-Ninot, Robert D Kilgour, Chloé Janiszewski, et al.
International Journal of Radiation Oncology, Biology, Physics|April 3, 2007
Cyclin D1 gene G870A polymorphism predicts response to neoadjuvant radiotherapy and prognosis in rectal cancerAlexandre Ho-Pun-Cheung, Eric Assenat, Simon Thezenas, et al.
The Oncologist|January 15, 2026
The BEVATOMOX phase II trial: raltitrexed/oxaliplatin/bevacizumab vs mFOLFOX6/bevacizumab in 2nd-line metastatic colorectal cancerEmmanuelle Samalin, Hélène Senellart, Simon Thezenas, et al.
Iscience|June 30, 2026
An exploratory study of circulating cell-free mRNAs across colorectal cancer stagesThibault Mazard, Marie Grosgeorges, Laura Veyrie, et al.
Pageof 6

Showing results (31-40 of 57) with videos related to

Sort By:
Pageof 6
Future Oncology (London, England)|February 5, 2014
Prognostic impact of the inclusion of uPA/PAI-1 tumor levels in the current adjuvant treatment decision-making for early breast cancerHaïdar Saadoun, Pierre-Jean Lamy, Simon Thezenas, et al.
Clinical Breast Cancer|January 2, 2018
Serum Vitamin D Levels Affect Pathologic Complete Response in Patients Undergoing Neoadjuvant Systemic Therapy for Operable Breast CancerAkiko Chiba, Rachna Raman, Alexandra Thomas, et al.
BMC Cancer|November 7, 2013
BRCA1 promoter hypermethylation, 53BP1 protein expression and PARP-1 activity as biomarkers of DNA repair deficit in breast cancerWilliam Jacot, Simon Thezenas, Romain Senal, et al.
Breast Cancer Research and Treatment|July 8, 2017
Prognostic impact of the inclusion of uPA/PAI-1 for adjuvant treatment decision-making in ER+/Her2- pN0 early breast cancersMarie Viala, Marie Alexandre, Simon Thezenas, et al.
BMC Cancer|February 1, 2019
The prognostic value of the Tau protein serum level in metastatic breast cancer patients and its correlation with brain metastasesAmélie Darlix, Christophe Hirtz, Simon Thezenas, et al.
The Oncologist|October 22, 2011
Cetuximab plus FOLFIRINOX (ERBIRINOX) as first-line treatment for unresectable metastatic colorectal cancer: a phase II trialEric Assenat, Francoise Desseigne, Simon Thezenas, et al.
Springerplus|July 9, 2016
Meal context and food preferences in cancer patients: results from a French self-report surveyEstelle Guerdoux-Ninot, Robert D Kilgour, Chloé Janiszewski, et al.
International Journal of Radiation Oncology, Biology, Physics|April 3, 2007
Cyclin D1 gene G870A polymorphism predicts response to neoadjuvant radiotherapy and prognosis in rectal cancerAlexandre Ho-Pun-Cheung, Eric Assenat, Simon Thezenas, et al.
The Oncologist|January 15, 2026
The BEVATOMOX phase II trial: raltitrexed/oxaliplatin/bevacizumab vs mFOLFOX6/bevacizumab in 2nd-line metastatic colorectal cancerEmmanuelle Samalin, Hélène Senellart, Simon Thezenas, et al.
Iscience|June 30, 2026
An exploratory study of circulating cell-free mRNAs across colorectal cancer stagesThibault Mazard, Marie Grosgeorges, Laura Veyrie, et al.
Pageof 6